摘要
目的:研究疏肝益阳(SGYY)胶囊治疗勃起功能障碍的分子机制。方法:选取3月龄成年雄性SD大鼠60只,采用双侧髂内动脉结扎法制造血管性勃起障碍模型。设假手术对照组、模型组、西药西地那非组(10.5mg.kg-1.d-1)、SGYY大剂量治疗组(1g.kg-1.d-1)、SGYY小剂量治疗组(0.5g.kg-1.d-1),每组12只,灌胃给药,疗程30d。取大鼠血浆,酶联免疫吸附(ELISA)法检测内皮素-1(ET-1)含量;取阴茎组织,实时荧光定量PCR(real-time PCR)法检测ET和连接蛋白43(CX43)mRNA表达。结果:3个治疗组与模型组比较,血浆ET-1含量显著降低(P<0.05,P<0.01),阴茎组织ET mRNA表达显著降低(P<0.01),CX43 mRNA表达显著升高(P<0.01)。结论:疏肝益阳胶囊可显著降低双侧髂内动脉结扎法制造的动脉性勃起障碍大鼠血浆ET-1含量和阴茎组织ET基因表达,并能显著增加阴茎组织CX43基因表达,这可能是其治疗血管性ED的机制之一。
Objective： To study the molecular mechanism of Shuganyiyang（SGYY） Capsule in treating ED.Methods： Bilateral ligation of the internal iliac artery was performed on sixty three-month old male Sprague-Dawley rats as an experimental group.The control group consisted of twelve rats which underwent dissection of the internal iliac artery without ligation.Rats in the experimental group were divided into model group,sidenafil group,SGYY high-dosage group（1g·kg-1·d-1） and low-dosage group（0.5g·kg-1·d-1）.After 30 days gavage,the plasma concentration of ET-1 in rats of each group was detected by ELISA,and expression of ET and CX43 mRNA in penis tissue of rats were detected by real-time PCR.Results： Plasma concentration of ET-1 was decreased in SGYY treatment groups compared to the model group（in high-dosage group P0.05,in low dosage group P0.01）.Expression of ET mRNA in penis tissue of rats was decreased in SGYY treatment groups compared to the model group（P0.01）.Expression of CX43 mRNA was increased in the SGYY treatment groups compared to the model group（P0.01）.Conclusion： SGYY can improve the expression of CX43,and decrease the expression of ET in rat model with arteriogenic erectile dysfunction,this probably is one of the mechanisms of the treatment of ED with SGYY capsule.
出处
《中华中医药杂志》
CAS
CSCD
北大核心
2011年第12期2948-2950,共3页
China Journal of Traditional Chinese Medicine and Pharmacy
